ABSTRACT: In the HIV-1 gp41 and other viral fusion proteins, the minimal oligomerization state is believed to be trimeric with three N-terminal fusion peptides inserting into the membrane in close proximity. Previous studies have demonstrated that the fusion peptide by itself serves as a useful model fusion system, at least to the hemifusion stage in which the viral and target cell lipids are mixed. In the present study, HIV-1 fusion peptides were chemically synthesized and cross-linked at their C-termini to form dimers or trimers. C-terminal trimerization is their likely topology in the fusogenic form of the intact gp41 protein. The fusogenicity of the peptides was then measured in an intervesicle lipid mixing assay, and the assay results were compared to those of the monomer. For monomer, dimer, and trimer at peptide strand/lipid mol ratios between 0.0050 and 0.010, the final extent of lipid mixing for the dimer and trimer was 2-3 times greater than for the monomer. These data suggest that the higher local concentration of peptide strands in the cross-linked peptides enhances fusogenicity and that oligomerization of the fusion peptide in gp41 may enhance the rate of viral/target cell membrane fusion. For gp41, this effect is in addition to the role of the trimeric coiled-coil structure in bringing about apposition of viral and target cell membranes. NMR measurements on the membrane-associated dimeric fusion peptide were consistent with an extended structure at Phe-8, which is the same as has been observed for the membrane-bound monomer in the same lipid composition.
Membrane fusion plays an essential role in enveloped virus entry into target host cells (1) (2) (3) (4) . Fusion is mediated by viral envelope proteins that contain apolar fusion peptide domains. The interaction between fusion peptides and lipids is believed to be one key event in initiating membrane fusion (5) . Recent studies suggest that fusion protein regions other than the fusion peptide also interact with membranes and play a role in fusion (6) (7) (8) (9) (10) .
For HIV-1 1 and other enveloped viruses, the free ∼20-residue fusion peptide has been shown to be a useful model fusion system, at least to the hemifusion stage in which there is significant mixing between the viral and the target cell lipids. The free peptide causes fusion of liposomes and erythrocytes, and numerous mutational studies have shown strong correlations between fusion peptide-induced liposome fusion and viral/host cell fusion (5, (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) .
For both the influenza hemagglutinin and the HIV-1 gp41 envelope proteins, there are crystal and NMR structures of soluble ectodomains in their fusogenic/final fusion conformations (26) (27) (28) (29) (30) (31) (32) . These trimeric coiled-coil structures represent ∼140-residue sequences that begin near the C-terminus of the fusion peptide and end near the N-terminus of the viral transmembrane domain. For the influenza viral fusion protein, a pre-fusion structure has also been observed and is different from the fusogenic/post-fusion coiled-coil structure (26, (32) (33) (34) (35) (36) . Comparison of these pre-and postfusion structures suggests movement of the fusion peptide from the interior to the exterior of the protein during fusion so that it can interact with target cell and possibly viral membranes. It is also possible that some of the energy released in the conformational changes is used during fusion. Crystallographic and immunological data suggest that there are also significant structural changes in the HIV-1 fusion proteins during fusion (37, 38) .
In the fusogenic coiled-coil structures, the N-and C-terminal ends of the soluble ectodomain are near one another, which implies that fusion peptide and viral transmembrane domains are in close proximity. With the assumption that the fusion peptide is in the target cell membrane, the structures also imply apposition of viral and target cell membranes, which is a reasonable geometry for membrane fusion.
In the present study, we explicitly consider another significant feature implied by the coiled-coil structure: an oligomeric fusion peptide topology with the C-termini of three fusion peptides in close proximity. The topology has been shown in recent models of membrane fusion (28, 30, 39) . Some of these models also consider multiple trimers at the fusion site that would create a high local concentration of fusion peptides (35, 36, 39) . In the present study, the C-terminal oligomerization topology was achieved in an HIV-1 fusion peptide model system with cysteine crosslinking.
In most fusion peptide studies to date, the peptides were synthesized as monomers. In membranes, they appear to have considerable structural plasticity and can exist as either monomeric helical or oligomeric strand or hairpin structures (5, (21) (22) (23) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) . Recently, a 127-residue FHA2 influenza fusion protein construct was also studied and included both the fusion peptide domain as well as the ∼100-residue C-terminal of the peptide (6, (53) (54) (55) (56) (57) (58) . Glutaraldehyde cross-linking showed that this construct is predominantly trimeric in either 2% n-octyl -D-glucoside or 0.5% Triton X-100 detergent. In 2% n-octyl -D-glucoside, cysteine crosslinking studies were consistent with a parallel trimeric arrangement of the helical region C-terminal of the fusion peptide. When a solution of 100 µM FHA2 in 0.1% Triton was added to a lipid vesicle solution, the induced lipid mixing was significantly higher than that induced by the influenza fusion peptide. In addition, the larger construct induces cellcell hemifusion. Collectively, these experiments support the hypothesis that an oligomeric topology of the fusion peptide may play a role in fusion.
MATERIALS AND METHODS

Materials.
Rink amide resin was purchased from Advanced Chemtech (Louisville, KY), and 9-fluorenylmethoxycarbonyl (FMOC)-amino acids were obtained from Peptides International (Louisville, KY). 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
, and N-(lissamine rhodamine B sulfonyl)-phosphatidylethanolamine (N-Rh-PE) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). The Micro BCA protein assay was obtained from Pierce (Rockford, IL). N-2-Hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES) and Triton X-100 were obtained from Sigma. All other reagents were analytical grade.
Peptides. Monomer peptides are denoted as FPmn. Several different constructs were synthesized: FP (AVGIGALFL-GFLGAAGSTMGARS), FPW (AVGIGALFLGFLGAA-GSTMGARSW), FPK3 (AVGIGALFLGFLGAAGSTM-GARSKKK), FPCK3 (AVGIGALFLGFLGAAGSTMGA-RSCKKK), FPCCK3 (AVGIGALFLGFLGAAGSTMGA-RSCCKKK), FPK3W (AVGIGALFLGFLGAAGSTMGAR-SKKKW), FPCK3W (AVGIGALFLGFLGAAGSTMGAR-SCKKKW), and FPCCK3W (AVGIGALFLGFLGAAGST-MGARSCCKKKW). These peptides were synthesized as their C-terminal amides using a peptide synthesizer (ABI 431A, Foster City, CA) equipped for FMOC chemistry. The sequences all contain the 23 N-terminal residues of the LAV 1a strain of HIV-1 gp41 and were sometimes followed by cysteine(s) for cross-linking and/or three lysines for enhanced solubility and/or a tryptophan as a UV/vis chromophore (59).
Peptides were cleaved from the resin in a 3-h reaction using a mixture of TFA/H 2 O/phenol/thioanisole/ethanedithiol in a 33:2:2:2:1 volume ratio. Peptides were subsequently purified by reversed-phase HPLC using a preparative C 18 column (Vydac, Hesperia, CA) and a water/acetonitrile gradient containing 0.1% TFA. Mass spectroscopy was used to verify peptide purity. Isotopically labeled forms of the peptides were also synthesized with a 13 C carbonyl label at Phe-8 and a 15 N label at Leu-9.
Cross-Linking. Figure 1 displays the cross-linking reaction schemes. Peptides at ∼5 mM concentration were cross-linked in 10 mM pH 8.2 DMAP buffer that was open to the atmosphere. Cross-linking was completed within 1 day. FPdm dimers were formed in a solution containing monocysteine peptide, and FPtr trimers were formed in a solution containing dicysteine peptide and monocysteine peptide in a 1:4 mol ratio. Cross-linked peptides of different masses were separated by reversed-phase HPLC with higher mass peptides eluting at higher acetonitrile concentrations. Cross-linked peptide masses were checked using SDS gels and mass spectrometry. For the peak identified as FPtr, greater purity was achieved with a second reversed-phase HPLC purification.
Lipid Preparation. A LM3 lipid/cholesterol mixture was used, which approximately reflects the lipid headgroup and cholesterol composition of the HIV-1 virus and its target T-cells (46, 60) . The LM3 mixture had POPC, POPE, POPS, sphingomyelin, PI, and cholesterol in a 10:5:2:2:1:10 mol ratio. Lipid and cholesterol powders were dissolved together in chloroform. The chloroform was removed under a stream of nitrogen followed by overnight vacuum pumping. Lipid dispersions were formed by addition of 5 mM pH 7.0 HEPES buffer containing 0.01% NaN 3 followed by homogenization with 10 freeze-thaw cycles. Large unilamellar vesicles (LUV) of 100-nm diameter were prepared by extrusion (61) .
Peptide Concentration Quantitation. Peptide concentrations were quantitated in three different ways: (1) BCA assay; (2) for FPtr (made from cross-linking FPCCK3W and FPCK3). The reproducibility of an absorbance measurement was (0.010 or typically (2%. When 280-nm absorbance gave FPmn, FPdm, and FPtr concentrations of 100, 50, and 25 µM, respectively, AAA typically gave concentrations of ∼90, 40, and 20 µM, respectively. Because AAA was considered to be the most accurate technique for absolute quantitation, concentrations determined by 280-nm absorbance for FPmn, FPdm, and FPtr solutions were multiplied by 0.9, 0.8, and 0.8, respectively. As will be presented in Figure 3 and Table  1 , similar fusion results were obtained when peptide was quantified by AAA and by the BCA assay.
Lipid Mixing Assay for Membrane Fusion. The resonance energy transfer (RET) assay of Struck et al. was used to monitor membrane fusion (62) . Two types of 100-nm diameter LM3 LUV were prepared. One set contained 2 mol % of the fluorescent lipid N-NBD-PE and 2 mol % of the quenching lipid N-Rh-PE, while the other set only contained unlabeled lipids. Fluorescently labeled and unlabeled vesicles were mixed in a 1:9 ratio. Following addition of peptide, lipid mixing between labeled and unlabeled vesicles caused dilution of the labeled lipids with a resulting increase of fluorescence. Fluorescence was recorded using 4-nm bandwidth on an Instruments S. A. Fluoromax-2 (Edison, NJ) spectrofluorimeter operating at excitation and emission wavelengths of 465 and 530 nm, respectively. A siliconized glass cuvette was used with continuous stirring in a thermostated cuvette holder. Measurements were carried out at 37°C with 2 mL of 150 µM lipid LUV in 5 mM pH 7 HEPES buffer. Peptide solution with initial concentration between 20 and 500 µM was added to the liposome solution to achieve the desired peptide/lipid mol ratio, and the change in fluorescence of the sample was monitored following this addition. The initial residual fluorescence intensity, F 0 , referenced zero lipid mixing. After addition of peptide, the fluorescence F(t) was monitored as a function of time (t). The maximum fluorescence intensity, F max , was obtained following addition of 20 µL of 10% Triton X-100. Percent lipid mixing at time t is denoted as M(t) and was calculated using When the peptide or Triton solution is added to the liposome solution, there are two competing effects on fluorescence: (1) increase because of lipid mixing and (2) decrease because of larger solution volume and corresponding lower fluorophore concentration. The largest added peptide solution volume was 60 µL, which increased the liposome solution volume by 3%. Experimentally, a 3% decrease in fluorescence was also observed when 60 µL of pure buffer was added to the liposome solution. In calculating M(t), F(t) and F max values were adjusted to take into account the small volume changes that occur upon addition of peptide and detergent. With sufficient time, M(t) reached a constant value that is denoted as M f , the final extent of lipid mixing. M f was used as a measure of peptide fusogenicity.
To make meaningful comparisons between the lipid mixing abilities of different peptides, the following protocols were developed: (1) the same sets of unlabeled and labeled liposomes were used for all of the peptides in each fusion assay; (2) peptide concentrations were adjusted so that the same volume of each peptide was added for a given peptide strand/lipid ratio; and (3) for each peptide and peptide strand/ lipid, two runs were made. The M f values for the two runs were usually within 2% of each other. The stock peptide solution concentrations varied between 20 and 900 µM, and M f appeared to be concentration-independent within this range. For most runs, peptide concentrations were ∼90 µM for FPmn, ∼40 µM for FPdm, and ∼20 µM for FPtr.
Solid State NMR Sample Preparation. Between 0.2 and 0.4 µmol of peptide was dissolved in ∼30 mL of 5 mM HEPES buffer (pH 7) that also contained 0.01% NaN 3 . LUV of LM3 (40 µmol of lipid) were prepared in ∼5 mL of buffer. The vesicle and peptide solutions were mixed and sat overnight at room temperature. The peptide/lipid mixtures were then ultracentrifuged at 100000g for 4 h so that the membrane and associated peptide pelleted. Pure FPmn or FPdm peptide solutions did not pellet under these conditions. The peptide/lipid pellet formed after ultracentrifugation was transferred by spatula to a 6-mm diameter magic angle spinning (MAS) NMR rotor.
Solid State NMR Spectroscopy. Chemical shifts were referenced to the methylene carbon resonance of adamantane (38.2 ppm). At room temperature and at 0°C, 13 C crosspolarization NMR signals were attenuated, presumably because of slow motion. Hence, measurements were made at -50°C where the samples are rigid and the 1 H spinlattice relaxation time is <1 s. With sufficient signal averaging time, spectra can also be obtained at room temperature and are similar to those observed at -50°C except that the lines are narrower. 
Experiments were done on a 9.4 T spectrometer (Varian Infinity Plus) using a triple resonance MAS probe. Spacers were placed in the 6-mm rotor so that the sample was restricted to the central 2/3 of the coil length (160 µL volume), and the 13 C and 15 N RF fields were reduced by at most 10% from their maximum values in the rotor center. The NMR detection channel was tuned to 13 C at 100.8 MHz, the decoupling channel was tuned to 1 H at 400.8 MHz, and the third channel was tuned to 15 N at 40.6 MHz. Experiments were carried out using a MAS frequency of 8000 Hz that was stabilized to (2 Hz. For the NMR experiments, peptides were 13 C carbonyl labeled at Phe-8 and 15 N amide labeled at Leu-9. NMR spectra were taken using a REDOR filter of the 13 C-15 N dipolar interaction so that the Phe-8 carbonyl was the only signal observed in the 13 C-detected REDOR difference spectrum (52, 63) . Between 1 and 2 ms of crosspolarization at 50 kHz was followed by a 1-ms REDOR dephasing period and then direct 13 C detection. A single 50-kHz 13 C refocusing π pulse was placed at the center of the dephasing time, and 1 H TPPM decoupling of 65 kHz was applied during both dephasing and detection (64) . The 13 C transmitter frequency was set to 155 ppm, and the 15 15 N π pulse at the middle and end of each rotor period, while the S 0 acquisition did not contain these pulses. XY-8 phase cycling was used for the 15 N pulses (65, 66) . During the dephasing period, pulses were not actively synchronized to the rotor phase. To obtain optimal compensation of B 0 , B 1 , and spinning frequency drifts, S 0 and S 1 FID values were acquired alternately. The recycle delay was 1 s. Figure 2b displays the 220-nm detected chromatogram of the cross-linking products formed from the reaction of FPCCK3W and FPCK3 in a 1:4 mol ratio. The largest peak corresponds to FPdm, while the following peak corresponds to the FPtr trimer. Again, this assignment was made by mass spectroscopy. In terms of increasing hydrophobicity, the molecules can be ordered FPmn, FPdm, and FPtr, and this also matches the ordering of the acetonitrile concentration at elution. Additional evidence for the trimer assignment was by made by detection of the chromatogram at 280 nm, as displayed in Figure 2c . In this chromatogram, the FPdm and FPtr peaks have approximately equal intensity. The peak intensities in panels b and c are qualitatively consistent with 220-nm detection of all FPtr and FPdm and 280-nm detection of all FPtr and only FPdm containing at least one FPCCK3W strand.
RESULTS
Synthesis and Characterization of Cross-Linked
As evidenced in Figure 2a , FPdm was the major product formed in cross-linking of either pure FPCK3W or FPCK3. Using 6 mg of monomer starting material, ∼3 mg of FPdm could be obtained after HPLC purification. FPtr was not the major product of cross-linking (cf. Figure 2b) , and after HPLC purification and repurification, ∼0.2 mg of FPtr was obtained from a cross-linking reaction that began with 15 mg of monomer starting material.
Analytical ultracentrifugation demonstrated that 75 µM FPK3W is predominantly monomeric in 5 mM pH 7 HEPES buffer. A mixture of monomer and higher order oligomerization states were observed for FPdm and FPtr at concentrations of 30 and 20 µM, respectively.
Fusion of LM3 Vesicles. In this case, peptide quantitation was made from AAA. At peptide strand/lipid ) 0.0050 and 0.010, FPdm has 2-3 times the fusogenicity of FPmn, while at 0.020 ratio, the enhancement factor is about 1.3.
The final extent of lipid mixing, M f , was used as a general measure of peptide fusogenicity. Figure 4 displays a plot of M f as a function of peptide strand/lipid mol ratio for assays using FPmn, FPdm, and FPtr with the same sets of liposomes. For these data, FPmn was FPK3W, FPdm was obtained from cross-linking FPCK3W, and FPtr was obtained from crosslinking FPCCK3W and FPCK3 in a 1:4 mol ratio. The fusogenicities of FPdm and FPtr are comparable over the experimental range of peptide strand/lipid mol ratios. At lower (e0.010) peptide strand/lipid ratios, FPdm and FPtr are significantly more fusogenic than FPmn while at ratios closer to 0.020, the fusogenicities of the three peptides are much more comparable.
When comparing runs using different sets of liposomes, there can be considerable variation in the M f values, even for the same peptide and peptide strand/lipid. A more meaningful measure is the ratio of the M f value of FPdm or FPtr to the M f value of FPmn. For runs from the same sets of liposomes, these fusogenicity ratios were calculated at peptide strand/lipid mol ratios of 0.0050, 0.010, and 0.020. In some runs, the data had been obtained at peptide strand/ lipid different than these three standard values so linear interpolation was used to calculate the fusogenicity ratios at the standard values. There was general consistency in the fusogenicity ratios among different liposome batches as evidenced in Table 1 , which displays the average values and standard deviations of the fusogenicity ratios. For example, the FPdm/FPmn fusogenicity ratio at peptide strand/lipid ) 0.010 represents the average of measurements taken with six different sets of liposomes. In addition, for a given peptide strand/lipid, the fusogenicity ratio is independent of the presence or absence of the C-terminal tryptophan in FPmn, FPdm, or FPtr and is also independent of the presence or absence of the cysteine in FPmn (cf. Figure 3a) .
Solid State NMR Measurements. Figure 5 displays solid state NMR REDOR difference spectra of LM3-associated FPmn and FPdm at peptide/lipid mol ratios of 0.009 and 0.004, respectively. The FPmn construct was FPK3W, and FPdm was made from cross-linking FPCK3W. Both FPmn and FPdm were 13 C carbonyl labeled at N amide labeled at Leu-9, and the REDOR-filtered difference spectra only show signals from the 13 C carbonyl labeled Phe-8. The displayed FPmn and FPdm spectra are very similar and have a peak centered at 171 ppm with 2.5 ppm line width (fullwidth at half-maximum). Similar spectra were obtained for other LM3-associated FPmn constructs including FP, FPK3, and FPW (data not shown). In Figure 5 , the FPdm spectrum shows partial resolution of three components, which is not apparent in the displayed FPmn spectrum. However, we have also observed these components in spectra of some other FPmn samples and hence conclude that they are not uniquely related to the FPdm.
Chemical shift correlation tables suggest that a 171 ppm Phe chemical shift is consistent with nonhelical structure (67) . In addition, solution NMR has shown that in detergent, FPmn is predominantly helical (40, 68) . In frozen detergent, the solid state NMR spectrum of labeled FPmn (FPKKK) yielded a sharp line whose peak chemical shift is 175 ppm (data not shown). In LM3, the peak chemical shift is 4 ppm lower, a difference that provides further evidence for nonhelical structure in LM3. Finally, for FPmn, previous solid state NMR 2-D exchange measurements were also consistent with nonhelical strand structure at Phe-8 (46) .
DISCUSSION
The topology of insertion of the HIV-1 fusion peptide is strongly suggested from high-resolution structures of the soluble portion of the gp41 ectodomain (27) (28) (29) (30) (31) . In this topology, the C-termini of three fusion peptides are near one another, and there is the possibility that the fusion peptides insert into the membrane in close proximity. In the present paper, we have synthesized fusion peptides that are crosslinked at their C-termini with a topology close to that found in the full protein. Relative to the monomer peptide, these cross-linked peptides enhance fusogenicity at least to the lipid mixing stage, which suggests that this topology may be a significant structural factor in catalyzing viral/target cell fusion. The studies in this paper consider the final extent of lipid mixing as a measure of fusogenicity, but in the future we also plan to carefully investigate the rates for buildup of lipid mixing. Preliminary analysis shows that these rates are generally larger for cross-linked peptides than for FPmn, and with further analysis and temperature-dependent studies, it may be possible to quantify the effect of topology on the activation energy of membrane fusion.
The enhanced fusogenicities of cross-linked fusion peptides are consistent with the hypothesis that lipid mixing induced by fusion peptides requires some critical local concentration of peptide strands associated with the membrane. For FPdm and FPtr, the local concentration is elevated by cross-linking so that relative to FPmn, the cross-linked peptides allow greater lipid mixing at lower peptide strand/ lipid. At higher peptide strand/lipid, FPmn, FPdm, and FPtr would all have surpassed the critical concentration and would have more similar fusion activities, which is consistent with experimental observation (cf. Figure 4 and Table 1 ). The proposed correlation between local peptide concentration and fusogenicity has some similarity to an earlier hypothesis that fusion requires a critical number of fusion peptides per vesicle (24) . However, this latter hypothesis predicts that at constant peptide/lipid, fusion will be greater for larger vesicles, and we observed that for FPmn, M f is independent of LM3 vesicle size (69) .
In addition to the higher local peptide concentration achieved with cross-linking, the overall concentration of cross-linked fusion peptide in LM3 could be higher than that of FPmn because of higher lipid affinity of the cross-linked peptide. However, there is some experimental evidence that points against different affinities of the different peptides. In the absence of LM3, BCA assay measurements showed that neither FPmn nor FPdm pellet under the ultracentrifugation conditions used to make the solid state NMR samples (46) . During preparation of FPmn (FP or FPKKK) NMR samples at 10 µM peptide and 1 mM lipid, BCA data also showed little peptide in the centrifugation supernatant (46, 69) . Taken together, these observations suggest quantitative association of FPmn with LM3. In addition, there was approximately the same NMR signal per scan for the FPmn and FPdm samples (cf. In related studies, other investigators have studied the lipid binding and fusogenicities of peptides that contained between 16 and 70 of the N-terminal residues of gp41 (7, 10) . Longer peptides had higher fusogenicities, but at 0.1 µM peptide concentration there were negligible differences in the lipid affinities of the different peptides. These data are similar to the different fusogenicities and comparable binding that we observed for FPmn and FPdm.
In more detailed molecular structural picture, there are at least two models that correlate cross-linking with enhanced fusogenicity. In one model, the main effect is greater peptide/ lipid interactions that lead to larger membrane disruption. For example, a splayed helix model for oligomers has noninteracting helices that insert obliquely into the membrane (56) . In a trimer, each helix forms an edge of a trigonal pyramidal structure.
In a second model, the topology correlates with a particular structural arrangement of interacting peptide strands, perhaps a parallel sheet structure. For FPmn, solid state NMR measurements have demonstrated that in LM3 at peptide/ lipid g0.010, the N-terminal and central regions of the peptide adopt a nonhelical strand structure (46) . In Figure  5 , the 1-D solid state NMR spectra for the Phe-8 carbonyl are very similar for LM3-associated FPmn and FPdm, which suggests that FPdm also forms a strand at this residue. Additional solid state NMR REDOR studies have shown that there are both parallel and antiparallel arrangements of strands in LM3-associated FPmn (69) . However, the C-terminal cross-linking topology of FPdm and FPtr suggests a parallel arrangement of strands. Furthermore, it is possible that the parallel alignment is more fusogenic than the antiparallel alignment. For the parallel arrangement, the apolar N-terminal regions of two or more peptide strands could insert into the hydrophobic interior of the membrane, which could be more disruptive to the membrane than a single peptide strand. This particular insertion topology is less likely with the antiparallel arrangement in which the polar and apolar ends of strands would be on the same side of the oligomer. Thus, FPmn, which has a mix of both parallel and antiparallel alignments, would be less fusogenic than FPdm and FPtr. The actual strand arrangement of the membrane-associated cross-linked peptides will be investigated by solid state NMR and other experimental methods. It is likely that any structure that inserts into the hydrophobic core of the membrane will require arrangements of strands in which most carbonyl oxygens and amide protons participate in inter-or intrapeptide hydrogen bonds. It is noted that in the solid state NMR experiments, the peptide structure is observed after vesicle fusion has occurred. It is also possible that fusion requires a transient structure that is different from the NMR structure observed at the end state of fusion.
At peptide strand/lipid mol ratios between 0.004 and 0.015, FPdm and FPtr have approximately the same fusogenicity (cf. Figures 3 and 4 and Table 1 ). This may be a general observation that the dimeric and trimeric topologies have approximately the same effect on lipid mixing. However, it is also noted that FPdm has an in-register strand alignment, whereas FPtr has one strand out of register with the other two strands (cf. Figure 1) . In gp41, the three strands are likely in-register, and it is possible that this arrangement is a structural requirement for enhanced fusogenicity. In the future, an in-register FPtr will be synthesized using differential cysteine protection and introduction of a spacer residue in the third strand (70) .
Our results suggest that oligomeric fusion peptide topology may have also contributed to the enhanced fusogenicity observed for the 127-residue FHA2 domain of influenza envelope protein (6, 56, 57) and for the construct containing residues 1-70 of gp41 (10) . In these systems, there is likely additional fusogenic enhancement because of the presence of other regions of the fusion protein. For the gp41 system, the overall fusogenicity of the 1-70 construct was about 10 times greater than that of the 1-23 construct, and this is a larger enhancement than we observed from cross-linking the 1-23 construct. In addition, although the 127-residue FHA2 induces cell-cell hemifusion, a 90-residue construct containing the fusion peptide and ∼70 C-terminal residues does not induce cell-cell hemifusion (57) . One possible explanation for this observation is that the 37 extra residues in FHA2 contain a kinked loop region that is required for pHdependent association of FHA2 trimers and for cell-cell hemifusion (6, 55, 56, 58) .
In this study as well as lipid mixing studies from other groups, it is possible that the oligomerization of peptides in aqueous solution prior to interaction with the target membrane impacts the rate and extent of lipid mixing. For our work, analytical ultracentrifugation demonstrated that FPmn (FPK3W construct) is predominantly a monomer in the assay buffer, whereas FPdm and FPtr are mixtures of monomeric and oligomeric cross-linked peptides. Thus, the possibility exists that some part of the enhanced fusogenicity of FPdm and FPtr is related to their oligomeric state in aqueous solution. However, studies of different FPmn peptide constructs that were either monomeric or oligomeric in aqueous solution did not show a clear correlation between M f and oligomeric state (69) . In addition, for the influenza fusion peptide, there does not appear to be a correlation between the peptide oligomeric state in aqueous solution and its final oligomeric state in the membrane, which suggests that oligomers can break up and/or (re)form at the membrane interface (71) . In the future, we plan to specifically address the effect of oligomerization by synthesis of cross-linked fusion peptides with longer C-terminal lysine sequences. Analytical ultracentrifugation of influenza fusion peptides showed that additional lysines could change the peptide from an oligomeric to a monomeric state in solution (data not shown). We expect that a similar effect may also be observed for the cross-linked HIV-1 fusion peptides.
In summary, we have shown a correlation between C-terminal cross-linking and enhanced fusogenicity of HIV-1 fusion peptides. The topology achieved through cross-linking is similar to the fusion peptide topology thought to exist in the fusogenic form of gp41. Thus, the topology may play a role in enhancing membrane fusion rates. The synthetic methodology described in this paper should be generally applicable to fusion peptides from other viruses. Less soluble peptide sequences (such as that from influenza) will require longer C-terminal guest lysine sequences. Because it is possible to obtain these cross-linked peptides in relatively high quantities, it is expected that structural and motional information about them will be readily obtained from techniques such as NMR, ESR, infrared, neutron diffraction, CD, and FRET, etc.
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